杨花花 周旭春 黄怡 文友飞

    [摘要]免疫机制在炎症性肠病(IBD)的发病中起着重要作用，生物制剂针对此机制起作用，治疗 IBD 疗效显著。虽然可供选择的生物制剂越来越多，但众多的生物制剂如何进行选择？对英夫利昔单抗(IFX)失应答的患者下一步治疗优先选择哪种生物制剂？本文从 IBD 的发病机制出发，对临床上常用的生物制剂进行总结和比较，以帮助临床医生做出选择。

    [关键词]炎症性肠病;发病机制;生物制剂;失应答

    [中图分类号] R574? [文献标识码] A? [文章编号]2095-0616(2022)08-0068-04

    Common biological agents for the treatment of inflammatorybowel disease

    YANG? Huahua? ZHOU? Xuchun? HUANG? Yi? WEN? Youfei

    1. Department of Gastroenterology， the First Affiliated Hospital of Chongqing Medical University， Chongqing 400016， China;2. Department of Gastroenterology， the Affiliated Hospital of Guizhou Medical University， Guizhou， Guiyang 550025， China

    [Abstract] Immune mechanisms play an important role in the pathogenesis of Inflammatory bowel disease (IBD). Biologics agents targeting the immune process are effective in the treatment of IBD. Although there are many biologics available， clinicians are often confused about how to choose from them？ Which biological agent is preferred for patients who fail to respond to Infliximab (IFX) in the next treatment？ In this paper， we will provide an overview of the pathogenesis ......